Erythropoiesis Stimulating Agents - Procrit, Epogen, and Aranesp

  1. Patients treated with an erythropoiesis-stimulating agent (ESA) and dosed to a target hemoglobin concentration of 13.5 g/dL are at a significantly increased risk for serious and life threatening cardiovascular complications, as compared to use of the ESA to target a hemoglobin concentration of 11.3 g/dL.

    More... Erythropoiesis Stimulating Agents - Procrit, Epogen, and Aranesp
    •  

close